Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7172508 in Advanced CEA-Positive Solid Tumors
NCT03539484Phase 1Terminated
- Sponsor
- Roche
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of RO7172508 in solid tumor (3 arms), sponsored by Roche. Primary endpoints: Dose Limiting Toxicities at 12 months and Adverse Events. Started Jul 2018; status: terminated.
02
Drugs
RO7172508
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03539484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539484.